Retrospective analysis of the effect of ABO blood group mismatch on transplant outcomes and transufusion requirements in a group of patients undergoing reduced intensity conditioning with alemtuzumab.
Phase of Trial: Phase IV
Latest Information Update: 26 May 2015
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine; Melphalan
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 26 May 2015 New trial record